Financial Performance - Revenue for Q4 2025 was $5.0 million, a decrease of 33.1% year over year, mainly due to lower CVD system revenue[3] - For the fiscal year 2025, revenue was $25.8 million, down 4.1% year over year, primarily due to lower SDC revenue[10] - The net loss for Q4 2025 was $1.3 million, or $0.18 per share, compared to a net income of $0.1 million, or $0.02 per share, in the prior year quarter[3] - The net loss for fiscal year 2025 was $1.6 million, or $0.23 per share, compared to a net loss of $1.9 million, or $0.28 per share, in fiscal year 2024[10] Orders and Backlog - Orders for Q4 2025 totaled $3.5 million, primarily driven by demand in the SDC business division for gas delivery equipment[3] - The backlog as of December 31, 2025, was $6.6 million, down from $8.0 million at September 30, 2025[3] Gross Margin - Gross margin for Q4 2025 was 22.1%, compared to 26.4% in the prior year quarter[3] Cash Position - Cash and cash equivalents as of December 31, 2025, were $8.7 million, down from $12.6 million as of December 31, 2024[10] Strategic Actions - The company entered into a definitive agreement to sell its SDC division for approximately $16.9 million in cash, expected to close in Q2 2026[6][7] - The company implemented a workforce reduction expected to reduce annual operating costs by approximately $1.8 million in fiscal 2026[3]

Financial Performance - The company reported net losses of $63.7 million and $44.0 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $156.6 million as of December 31, 2025[260]. - The company has not generated any revenue to date and does not expect to do so until at least one product candidate is successfully commercialized[269]. - As of December 31, 2025, the company had $226.8 million in cash, cash equivalents, and marketable securities, which, along with approximately $335.3 million from its IPO, is expected to fund operations into 2029[266]. - Future capital requirements may increase significantly due to various factors, including the costs of clinical trials and regulatory approvals[267]. - The company may need to raise additional capital sooner than planned if preclinical and clinical activities take longer than expected[264]. Product Development and Clinical Trials - The lead product candidate, [225Ac]Ac-AKY-1189, is currently in a Phase 1b clinical trial for locally advanced or metastatic urothelial cancer and other Nectin-4 expressing tumors[259]. - The company anticipates significant increases in expenses as it advances its product candidates through clinical trials and expands its operational capabilities[260]. - The success of the company’s product candidates heavily relies on timely regulatory approvals and the ability to manufacture adequate clinical and commercial supplies[277]. - The process for obtaining marketing approval for [225Ac]Ac-AKY-1189 is lengthy and risky, with no guarantee of success in clinical trials[280]. - The company must complete clinical trials and obtain regulatory approval before commercialization, which is subject to significant challenges and uncertainties[283]. - Delays in clinical trials can arise from various factors, including regulatory authorization, patient recruitment, and compliance with clinical protocols[285]. - The company is conducting clinical trials for product candidates [225Ac]Ac-AKY-1189 and [225Ac]Ac-AKY-2519, but there is a risk that these trials may not demonstrate sufficient safety and efficacy for regulatory approval[294]. - The Phase 1b clinical trial for [225Ac]Ac-AKY-1189 is an open-label trial, which may introduce biases that could affect the interpretation of results[294]. - There is a limited historical experience with radiopharmaceutical therapeutics, making the design and conduct of clinical trials uncertain and subject to increased risk[296]. - The company acknowledges that most product candidates entering clinical trials do not receive regulatory approval, and unforeseen side effects could arise during or after trials[294]. Regulatory and Compliance Risks - The company faces risks related to unforeseen expenses and delays in clinical trials, which could adversely affect its business and financial condition[261]. - The FDA's Project Optimus initiative may require the company to conduct dose optimization studies, potentially delaying product development activities[288]. - Regulatory approval for product candidates like [225Ac]Ac-AKY-1189 will involve ongoing obligations and significant expenses related to compliance and post-marketing requirements[349]. - Compliance with cGMP regulations is mandatory for manufacturing facilities, requiring continuous review and inspections[350]. - Changes in legislation or regulatory policies could lead to significant penalties, including product recalls or withdrawal of regulatory approvals[351]. - The regulatory approval process for pharmaceutical products is lengthy and unpredictable, posing risks to the company's ability to commercialize products[334]. - The company must navigate complex state and federal laws regarding pharmaceutical marketing and pricing, which may vary significantly across jurisdictions[372]. Market and Competitive Landscape - The commercial success of [225Ac]Ac-AKY-1189 will depend on acceptance by the medical community and the ability to demonstrate efficacy and cost-effectiveness compared to existing treatments[316]. - The company may face significant competition from other firms developing targeted alpha-based radiopharmaceuticals, which could impact market position[322]. - Market opportunities for product candidates may be smaller than anticipated, particularly if targeting patients who have failed prior treatments[325]. - The company has never commercialized a product candidate, which poses risks in obtaining regulatory approval and could delay revenue generation[326]. - The company currently lacks marketing and sales capabilities, which may hinder its ability to generate product revenue if product candidates are approved for commercial sale[327]. Intellectual Property and Patent Risks - The company currently owns one issued patent related to AKY-1189 and has no issued patents for AKY-2519 as of March 1, 2026[436]. - Patent applications may not result in issued patents, and existing patents may not provide sufficient protection against competitors[439]. - The company does not own or expect to own any issued patents relating to the radioactive payload, 225Ac, used in its product candidates[435]. - The introduction of the Unitary Patent system in Europe increases uncertainty regarding patent litigation outcomes[441]. - The patent application process is expensive, time-consuming, and complex, which may hinder the ability to file and maintain necessary patent applications[444]. - There is uncertainty regarding the patentability of claims in pending applications, which could adversely affect the commercialization of product candidates[443]. Supply Chain and Manufacturing Challenges - The company plans to scale up its supply of 225Ac and other radioisotopes and expand partnerships with isotope suppliers to enhance its supply chain[260]. - The company relies on U.S.-based third-party manufacturers for the production of its product candidates, which poses risks related to maintaining agreements and ensuring compliance with FDA regulations[414]. - Any interruption in supply from third-party manufacturers could delay clinical trials and commercial supply, adversely impacting business operations[417]. - The company may face challenges in obtaining sufficient supplies of 225Ac, a key component for its product candidates, which could hinder clinical development and commercialization efforts[422]. - Manufacturing biologics is complex and costly, with potential supply disruptions due to reliance on third-party manufacturers[413]. Data Privacy and Cybersecurity - The company faces significant compliance costs related to evolving data privacy and cybersecurity laws, which could adversely affect its operations and financial performance[386]. - The California Consumer Privacy Act (CCPA) imposes civil penalties of up to $7,500 per violation, impacting the company's compliance costs and business activities[392]. - The General Data Protection Regulation (GDPR) and UK GDPR impose stringent operational requirements for data processing, which may increase compliance costs and risks for the company[395]. - The company must navigate a complex landscape of federal, state, and international data privacy regulations, which could lead to significant penalties and reputational harm if not adhered to[390]. Healthcare Regulations and Legislative Changes - The Patient Protection and Affordable Care Act (ACA) has significantly impacted the U.S. pharmaceutical industry, particularly in terms of payment methodologies and research promotion[371]. - Legislative changes to the ACA, such as the "One Big Beautiful Bill Act," are expected to reduce Medicaid spending and limit access to ACA marketplace enrollment[374]. - The Inflation Reduction Act of 2022 includes provisions for negotiating drug prices under Medicare, which may significantly impact the pharmaceutical industry[375]. - Recent legal challenges to FDA approvals, such as the case involving mifepristone, could affect the company's ability to develop and market new drug products[376]. - Changes in federal agency leadership may lead to new policies and regulations that could materially impact the pharmaceutical industry and the company's operations[377].

Financial Performance - ARKO Parent's retail segment generated total revenues of $4.4 billion for the year ended December 31, 2025, including $1.5 billion from in-store sales and other revenues[45]. - ARKO Parent sold 0.9 billion gallons of branded and unbranded fuel to its retail customers during the same period[45]. - For the year ended December 31, 2025, cash flows provided by operating activities were $79.6 million, a decrease from $106.8 million in 2024, attributed to higher net interest payments and changes in working capital[343]. - Discretionary Cash Flow for the year ended December 31, 2025, was $88.9 million, compared to $79.9 million in 2024 and $86.5 million in 2023[345]. Liquidity and Capital Structure - As of December 31, 2025, the company had liquidity of $434.3 million, consisting of approximately $15.6 million in cash and cash equivalents and approximately $418.7 million available under the Capital One Line of Credit[38]. - As of December 31, 2025, the company had a strong liquidity position of approximately $434.3 million, consisting of $15.6 million in cash and cash equivalents and $418.7 million of unused availability under its $800 million Capital One Line of Credit[337]. - The company reported indebtedness of $542.1 million, resulting in a total debt to net income ratio of 12.0x and a net debt to adjusted EBITDA ratio of 3.7x for the year ended December 31, 2025[38]. - As of December 31, 2025, all debt bore interest at variable rates, exposing the company to interest rate risk[337]. - The company expects future capital requirements to be financed through cash on hand, cash generated by operations, and additional long-term debt as necessary[339]. Capital Expenditures and Investments - Total capital expenditures for the year ended December 31, 2025, were approximately $24.8 million, including the purchase of six fee properties for $6.5 million[347]. - Cash flows used in investing activities increased by $12.7 million to $22.2 million in 2025 from $9.4 million in 2024, reflecting increased capital expenditures[347]. Debt and Credit Facilities - The Capital One Line of Credit has an aggregate principal amount of up to $800 million, which can be increased to $1.0 billion[363]. - Approximately $380.8 million was drawn on the Capital One Line of Credit as of December 31, 2025, with $418.7 million available[364]. - The M&T Credit Agreement provides a line of credit for up to $45.0 million, with approximately $32.9 million remaining available as of December 31, 2025[352]. - The PNC Line of Credit has an aggregate principal amount available of up to $84 million, with a maturity date of February 13, 2031[360]. - The interest on the Capital One Line of Credit can range from 1.25% to 3.25% depending on the elected rate[365]. - The ARKO Parent Intercompany Notes were issued in an aggregate principal amount of $14.9 million, reflecting the portion of the debt under the M&T Credit Agreement attributable to the Business[358]. - The M&T Term Loans began to accrue interest at SOFR plus 2.25% following the amendment[355]. - The PNC Line of Credit requires maintaining certain financial covenants, including a leverage ratio and an interest coverage expense ratio[367]. - The Capital One Line of Credit allows for the use of proceeds up to $18 million per fiscal year for dividends[367]. Business Transformation and Growth - The wholesale segment grew by 256 sites through the conversion of ARKO Retail Sites to dealer locations as part of ARKO Parent's multi-year transformation plan[38]. - The company has successfully converted 409 ARKO Retail Sites to dealer locations from mid-2024 through December 31, 2025, with plans for further conversions in 2026[46]. - The U.S. wholesale fuel distribution industry is highly fragmented, with approximately 6,500 domestic wholesale fuel distributors as of the end of 2025[43]. - The largest distributor in the industry holds only an 8% market share, indicating significant consolidation opportunities[43]. - The company benefits from strong relationships with major oil companies, allowing it to offer competitive pricing and terms to its customers[42]. Dividend Policy - The Board declared a quarterly pro-rated dividend of $0.26 per share, with an intention to pay a regular quarterly cash dividend of $0.50 per share, or $2.00 per share on an annualized basis[338].

Revenue Performance - SaaS revenue increased 8.4% year over year to $1.6 million in Q4 2025, contributing to total revenue of $4.3 million, which is a 1.0% increase compared to Q4 2024[10][11] - For the full year 2025, total revenue was $16.6 million, reflecting an 8.0% decrease from $18.0 million in 2024, primarily due to lower professional services activity[15][16] - Professional services revenue decreased 1.8% year over year in Q4 and 18.7% year over year for the full year 2025[10][16] - Total revenues for 2025 decreased to $16,583,446 from $18,018,373 in 2024, representing a decline of approximately 8%[30] - Software as a service revenue increased to $6,331,167 in 2025, up from $5,688,936 in 2024, reflecting a growth of about 11.3%[30] Profitability and Loss - The net loss for Q4 2025 was $207,975, or ($0.05) per share, compared to a net loss of $53,701, or ($0.01) per share in Q4 2024[10][13] - Adjusted EBITDA for Q4 2025 was $260,749, down from $531,241 in Q4 2024, while for the full year it was $469,694 compared to $2,382,357 in 2024[10][26] - Net loss for 2025 was $1,872,895, compared to a net loss of $546,215 in 2024, indicating a significant increase in losses[30] - The company reported a basic net loss per share of $0.44 for 2025, compared to $0.13 for 2024[30] Operating Expenses - Total operating expenses increased 11.2% in Q4 2025 to $3.1 million, driven by a 14.4% increase in sales and marketing expenses[12] - Operating expenses rose to $12,741,153 in 2025, compared to $11,541,889 in 2024, an increase of approximately 10.4%[30] Assets and Liabilities - Total current assets decreased to $5,229,257 in 2025 from $5,474,556 in 2024, a reduction of approximately 4.5%[28] - Total liabilities decreased to $5,921,556 in 2025 from $7,943,201 in 2024, a decline of about 25.5%[28] - Total stockholders' equity increased to $11,384,016 in 2025 from $10,631,755 in 2024, an increase of about 7.1%[28] Cash Flow - Cash provided by operating activities for 2025 was $933,871, down from $3,858,160 in 2024, a decrease of approximately 75.8%[32] - Cash at the end of the period increased slightly to $2,528,281 in 2025 from $2,489,236 in 2024[32] Strategic Focus - Management expects SaaS revenue to continue growing year over year in fiscal year 2026[17] - The company secured a significant contractual win with its largest customer, strengthening its document management business[5][7] - Intellinetics is focusing on improving execution and refining its go-to-market approach to enhance long-term growth and revenue predictability[6][9]

Financial Performance - The Company has a history of net losses and Adjusted EBITDA losses, indicating challenges in achieving growth objectives[45]. - Financial performance in 2023 fell short of expectations, with a 5-year average revenue of $12,175,532 per year, impacted by macroeconomic factors such as high interest rates and supply chain issues[70]. - The company reported a working capital of $5,026,580 as of December 31, 2023, indicating a strong liquidity position for ongoing operations and R&D initiatives[79]. - The company reported net earnings of $447,397 for the year ended December 31, 2025, a significant recovery from a net loss of $4,622,297 in 2024[111]. - For the year ended December 31, 2025, the Company reported revenues of $10,784,090, a slight increase from $10,680,468 in 2024, indicating stability in the business model[140]. - The gross profit for 2025 was $4,432,744, representing a gross profit margin of 41%, down from 44% in 2024[149]. - Total expenses for 2025 were $3,989,053, significantly reduced from $5,527,559 in 2024, primarily due to decreased consulting and administrative costs[150]. - The Company achieved a gross profit margin of 44% on revenues of $10,680,468 for the year ended December 31, 2024, up from 42% on revenues of $10,819,916 in 2023[158]. Operational Challenges - The Company may not have sufficient capital to meet increases in business demands, potentially affecting its ability to grow operations[44]. - The Company’s production facilities may not be large enough to handle growth in market demand, impacting revenue generation[53]. - The Company may face shortages of parts and raw materials, which could hinder business development plans and revenue[52]. - The Company is subject to risks from customer order cancellations, which could negatively impact revenue if component parts have already been ordered[49]. - The Company may encounter unforeseen competition that could affect its ability to maintain projected revenue levels[48]. - The Company may face risks related to international conflicts and geopolitical tensions, which could disrupt supply chains and impact financial performance[41]. Research and Development - The Company invests in R&D activities focused on innovation, but returns on these investments are uncertain and may not yield immediate financial performance[39]. - The Company has made considerable progress in R&D for new products, although the timing of regulatory approvals remains unpredictable[77]. - The Company has impaired its capitalized research and development (R&D) to a nominal $1, reflecting challenges in securing funding for the KXI project[90]. - The Company is actively exploring strategic alternatives for the KXI project, including potential joint ventures and licensing agreements[90]. - The Company plans to continue developing new rail products to create financial growth opportunities despite current market challenges[143]. Product Development and Market Strategy - The K2AV product is on track to complete its field service trial by 2025, with AAR approval expected to significantly increase revenue potential from pressure cars, raising average sales from $1,500 to over $10,000 per car[82]. - The Company aims to leverage its competitive advantages in the rail industry despite challenges, with a focus on diversifying its product portfolio and obtaining AAR approvals for new products[81]. - The Company plans to strengthen its tank car product portfolio with ongoing field service trials for new valves, which are expected to generate higher unit sales and increase revenue[84]. - The tank car market is shifting towards repurposing and re-qualifying existing fleets, presenting revenue growth opportunities for the Company in repair and retrofit services[86]. - The Company has capitalized on the need for safer valve solutions, generating over $147 million in revenues since 2012 from distributing over 100,000 valves[120]. Financial Management and Capital Resources - The Company has increased its line of credit with Texas Capital Bank from $500,000 to $1 million, indicating improvements in fiscal management[99]. - The Company anticipates that its capital resources will enable it to continue operations as planned for the foreseeable future[171]. - The Company’s working capital increased to $2,541,625 in 2025 from $2,125,387 in 2024, reflecting improved liquidity[140]. - The Company had cash on deposit of $399,375 and inventory of $2,206,770 as of December 31, 2025, compared to cash of $153,147 and inventory of $3,042,749 as of December 31, 2024[170]. Executive Compensation and Governance - Frank Busch serves as the Director, President, and CEO, with a total compensation of $300,000 for Fiscal Year 2025[189]. - Sameer Uplenchwar, the Chief Financial Officer, has a total compensation of $240,000 for Fiscal Year 2025[189]. - Amanda Smith, the Chief Operating Officer, received a total compensation of $222,879 for Fiscal Year 2025[189]. - The Company has entered into Professional Services Agreements with its executives, ensuring structured compensation and performance incentives[190][192]. - The Company has a severance clause for executives equal to 6 months of base salary in the event of termination without cause[190]. - The Compensation Committee is responsible for overseeing compensation policies approved by the Board[226]. Audit and Compliance - The Audit Committee is responsible for reviewing both interim and annual financial statements, with members having the right to inspect all books and financial records of the Company[224]. - The former auditors, Smythe LLP, resigned on September 25, 2025, and were replaced by CBIZ CPAs P.C. effective October 6, 2025[225]. - The Committee reviews the financial reporting process to ensure the accuracy of the Company's financial statements[226]. - It evaluates the independent auditor's qualifications, performance, and independence[226]. - The Committee monitors compliance with laws and regulations[226].

Financial Performance - Net sales for 2025 were $10,142, an increase of $769, or 8.2%, from $9,373 in 2024, driven by higher sales of wired sensing products and HazardPRO™ wireless systems[73] - Gross profit for 2025 increased $575, or 12.5%, to $5,157 from $4,582 in 2024, with a gross margin of 50.8% compared to 48.9% in 2024[75] - Total operating expenses increased $569, or 12.4%, to $5,155 in 2025 from $4,586 in 2024, rising as a percentage of net sales to 50.8% from 48.9%[76] - Operating income was $2 in 2025 compared to an operating loss of $4 in 2024, marking an increase of $6, or 150.0%[78] - Net income decreased by $140, or 31.4%, to $306 in 2025 from $446 in 2024, with basic and diluted earnings per share at $0.09 and $0.13, respectively[82] Cash and Liquidity - Cash and cash equivalents were $10,545 at December 31, 2025, compared to $9,948 at December 31, 2024, with working capital increasing to $13,468 from $12,922[84] - Cash generated from operating activities was $662 in 2025, an increase of $533 from $129 in 2024[85] - Cash equivalents as of December 31, 2025, were $7,985,000, compared to $7,980,000 in 2024, showing a slight increase[125] Assets and Equity - Total assets increased to $15,702,000 in 2025 from $14,885,000 in 2024, representing a growth of 5.5%[111] - Total stockholders' equity grew to $14,817,000 in 2025, up from $14,333,000 in 2024, an increase of 3.4%[111] - Trade receivables, net of allowance for credit losses, increased to $1,404,000 in 2025 from $1,309,000 in 2024, a rise of 7.3%[111] Expenses and Investments - Total operating expenses totaled $5,155,000 in 2025, compared to $4,586,000 in 2024, an increase of 12.4%[113] - Research and development expenses were $991,000 in 2025, down from $1,013,000 in 2024[145] - The Company believes its ongoing cash usage requirements will be primarily for capital expenditures, potential acquisitions, and research and development[87] Taxation - Total Federal and State Income Taxes for 2025 amounted to $41,000, compared to a tax provision of $(10,000) in 2024, reflecting a significant increase[10]. - The computed "Expected" Federal Tax Expense for 2025 was $73,000, representing 21.0% of pretax income, slightly down from $92,000 or 21.1% in 2024[10]. - The net deferred tax asset as of December 31, 2025, was $464,000, a decrease from $501,000 in 2024, primarily due to changes in R&D expenses and valuation allowances[13]. Corporate Governance - Management's assessment confirmed that internal controls over financial reporting were effective as of December 31, 2025, ensuring compliance with SEC regulations[20]. - The Audit Committee is comprised of independent directors, ensuring oversight and compliance with financial reporting standards[22]. - The Company has adopted a Code of Ethics and Business Conduct applicable to all employees, reinforcing its commitment to ethical practices[21]. Compensation and Incentives - The total compensation for David L. Klenk, President and CEO, in 2025 was $354,468, an increase from $316,916 in 2024, driven by a higher bonus[16]. - The 2025 Plan allocated 40% of the potential bonus to financial performance, 50% to strategic initiatives, and 10% was discretionary, with an incentive cash payment of approximately 18% of Mr. Klenk's base salary[221] - The 2026 Management Incentive Plan allocates 50% of the potential bonus to financial performance, 40% to strategic initiatives, and 10% is discretionary, with an incentive cash payment of approximately 21% of Mr. Klenk's base salary if goals are achieved[222] Audit and Compliance - The Company paid $124,370 in audit fees to Boulay PLLP for 2025, an increase from $107,000 in 2024[240] - Total fees paid to Boulay PLLP in 2025 amounted to $133,370, compared to $121,135 in 2024[240] - The independent auditor will provide statutory and financial audits, as well as audit services related to SEC registration statements and periodic reports[47]

Financial Performance - The company reported a significant increase in revenue, achieving $1.5 billion for the year ended December 31, 2025, representing a 15% growth compared to the previous year[8]. - The company reported a net income of $400 million, reflecting a 12% increase year-over-year, driven by operational efficiencies and cost management[8]. - Gold Fields reported a significant increase in production, achieving a total output of 2.5 million ounces of gold, representing a 10% increase year-over-year[90]. - Gold Fields reported a strong performance with a revenue increase of 15% year-over-year, reaching $1.2 billion in Q3 2023[178]. - The company reported a 20% increase in cash flow from operations, totaling $500 million, driven by higher gold prices and operational efficiencies[90]. Future Projections and Guidance - The company provided guidance for 2026, projecting revenue growth of 10-12% based on anticipated market conditions and product demand[9]. - The company anticipates a production guidance of 2.6 million ounces for the next fiscal year, reflecting a growth of 4%[90]. - The company plans to increase production by 10% in 2026, driven by operational improvements and new technology implementations[119]. - The company provided an optimistic outlook for Q4 2023, projecting revenue growth of 10% to 12%[178]. Market Expansion and Strategic Initiatives - The company plans to expand its market presence in Asia, targeting a 25% increase in market share within the next two years[9]. - New product launches are expected to contribute an additional $200 million in revenue, with a focus on innovative technologies in the mining sector[9]. - The company is focusing on expanding its operations in Peru, with an investment of $300 million planned for the next three years to enhance mining capabilities[90]. - Market expansion efforts include entering three new international markets, projected to increase market share by 5%[178]. Sustainability and Environmental Initiatives - Environmental initiatives are being prioritized, with a commitment to reduce carbon emissions by 30% by 2026[9]. - The company has set ambitious sustainability targets, aiming for a 30% reduction in greenhouse gas emissions by 2026[90]. - The company is committed to reducing its carbon footprint by 30% by 2030, aligning with global sustainability goals[111]. - A new sustainability initiative is set to reduce operational costs by 8% over the next two years[178]. Governance and Ethical Practices - The board emphasized the importance of ethical governance and stakeholder engagement in its annual report, highlighting a commitment to responsible mining practices[7]. - The company is committed to ethical business practices, with robust mechanisms in place to ensure regulatory compliance and good governance principles[163]. - The Board is focused on fair remuneration practices aligned with strategy and promoting business performance, ensuring transparency in executive remuneration[176]. - The company is committed to ethical business practices and good governance as part of its strategic initiatives[180]. Operational Efficiency and Cost Management - Capital expenditures for 2026 are projected at $300 million, aimed at enhancing operational efficiency and expanding production capacity[8]. - The company is focused on enhancing operational efficiencies and asset optimization to manage cost pressures while maintaining strong production levels[135]. - The company is enhancing stakeholder engagement through a new Business Partner Framework aimed at improving collaborative relationships[156]. Acquisitions and Investments - The company is exploring strategic acquisitions to bolster its portfolio, with a budget of $500 million allocated for potential mergers and acquisitions[9]. - Gold Fields is actively pursuing strategic acquisitions to enhance its mineral resource base, with a target of increasing reserves by 15% over the next five years[90]. - The company is considering strategic acquisitions to bolster its technology portfolio, with a budget of $100 million allocated for potential deals[178]. - Gold Fields completed the acquisition of Gold Road Resources, consolidating 100% ownership of the Gruyere asset, which is expected to enhance the quality of its portfolio[139]. Safety and Community Impact - The total recordable injury frequency rate (TRIFR) improved to 2.5 per million hours worked, indicating a 15% reduction in workplace injuries[86]. - The company reported no work-related fatalities in 2025, marking a significant milestone in its safety performance[133]. - Gold Fields' socio-economic development spend reached $20 million, enhancing community relations and local development initiatives[105]. Board and Leadership Structure - The Board currently comprises 13 directors, including 2 executive directors and 11 independent non-executive directors (NEDs)[181]. - The Board has maintained a majority of independent NEDs since the Company's inception, ensuring independent judgment in discussions and decisions[182]. - The Board's diversity targets include 30% female representation across the workforce by 2030[184]. - The Board's governance structure emphasizes adherence to sound corporate governance standards and effective oversight of business operations[192].

Financial Performance - Fourth quarter net income improved to $0.9 million compared to a net loss of $0.3 million in the prior year period[1] - Revenue for the fourth quarter was $1.50 million, a decrease of approximately 11.0% from $1.68 million in the prior year, primarily due to a shift in the Amazon business model[5] - Gross profit for the fourth quarter was $0.67 million, with a gross margin of 44.9%, down 1400 basis points year-over-year[5] - Full-year revenue increased to $6.61 million, reflecting a 0.7% increase from $6.57 million in the prior year[5] - The company reported a gross profit of $3.48 million for the full year, with a gross margin of 52.7%, down 220 basis points year-over-year[5] - Net income for the year ended December 31, 2025, was $758,478, compared to a net loss of $559,356 in 2024[16] Assets and Liabilities - Total assets increased to $9.11 million as of December 31, 2025, compared to $7.17 million in the prior year[12] - Total liabilities rose to $7.57 million from $7.29 million in the previous year[12] - Stockholders' equity improved to $1.54 million from a deficit of $0.12 million in the prior year[12] Cash Flow and Financing - Cash flows from operating activities resulted in a net cash used of $1,271,544, a significant decrease from a net cash provided of $1,990 in the previous year[16] - Total cash at the end of the period increased to $2,726,696 from $211,642 at the beginning of the period[16] - The company recorded a significant financing activity with proceeds from the issuance of preferred stock amounting to $8,000,000[16] - The company incurred a deferred offering cost of $1,721,228, compared to $163,125 in the previous year[16] - Stock-based compensation increased to $543,068 from $414,900 year-over-year[16] - The company reported a loss on the issuance of preferred stock of derivative liabilities totaling $5,294,242[16] - Cash paid for interest increased to $401,411 from $224,428 in the previous year[16] - The company recognized a derivative liability of preferred stock amounting to $13,294,242[17] - Common stock was issued for convertible note payable and accrued interest totaling $122,331[17] Product Development - The company launched Tru2u.health, a digital health platform, in February, integrating various health solutions into a seamless consumer experience[6] - The Kirkman brand portfolio was expanded with two new product bundles, enhancing market offerings[6]

Financial Position and Debt - As of December 31, 2025, OPC had outstanding indebtedness of $1,769 million, with an additional $1,376 million in debt from CPV's associated companies[88]. - Kenon's stake in OPC decreased from approximately 55% at the beginning of 2025 to approximately 46% due to participation in only one of four equity capital raises conducted by OPC[63]. - OPC and its subsidiaries require additional financing for ongoing construction and development projects, which may impact their operational strategies[62]. - The company relies on cash flows from its businesses to meet obligations, and any limitations on distributions could affect its financial flexibility[83]. - High levels of leverage increase sensitivity to market conditions, with significant portions of cash flows used for debt service, limiting operational funding[89]. - The ability to execute future investments or acquisitions may depend on obtaining necessary regulatory approvals and favorable financing conditions[74]. - As of December 31, 2025, OPC had $1,769 million in consolidated indebtedness, which may affect its ability to comply with financial covenants[133]. - High leverage levels pose risks to OPC's ability to secure funding for future strategic plans, potentially impacting credit ratings and operational results[159]. - OPC's dependency on dividends from subsidiaries may limit cash flow availability, affecting its ability to meet liabilities[161]. Market and Economic Risks - Disruptions in financial markets could adversely affect the ability of OPC and Kenon to access capital on acceptable terms, impacting liquidity and investment strategies[77]. - Global economic conditions, including geopolitical events and commodity price fluctuations, could adversely affect the company's business and operating results[108]. - The ongoing military conflicts and their impact on supply chains may lead to project delays and operational disruptions[112]. - Global geopolitical instability, including conflicts and economic uncertainty, may disrupt OPC's supply chain and financing availability[162]. - The political and security situation in Israel could adversely impact OPC's operations and financial stability, affecting project execution and compliance with financing agreements[166]. Operational and Regulatory Challenges - The company faces risks related to potential acquisitions or investments, including the challenge of identifying suitable opportunities and the potential for unfavorable terms[70]. - OPC's operations are significantly influenced by government regulations, with recent changes in the tariff structure in Israel impacting its results[139]. - The company may face limitations in raising debt financing due to regulatory restrictions imposed on financial institutions regarding loans to single borrowers[136]. - OPC's ability to expand its business may be limited by existing regulations, including competition laws and the Electricity Sector Law in Israel[149]. - OPC's operations are subject to increasing scrutiny regarding environmental, social, and governance (ESG) goals, which may affect its financing and operational costs[137]. - Legal and compliance risks are prevalent, with potential enforcement actions and penalties that could disrupt operations and increase costs[122]. - Changes in international sanctions and trade restrictions could expose OPC to civil or criminal penalties, adversely affecting financial condition and operations[128]. Supply Chain and Resource Risks - The company faces risks related to raw material shortages and supplier capacity constraints, which could increase operating costs[114]. - OPC faces risks related to supply chain disruptions, including reliance on limited suppliers for raw materials, which could increase operating costs and affect product quality[116]. - Fuel supply disruptions and price fluctuations, particularly for natural gas, may adversely impact OPC's operating results[211][213]. - OPC relies on key suppliers for construction and maintenance, and any failure to meet performance targets may lead to project delays and financial losses[216]. - The ability to secure grid connections and infrastructure is critical for OPC's operations, with potential adverse effects from disruptions or insufficient capacity[217][219]. Cybersecurity and Technological Risks - Cybersecurity threats are increasing, with potential attacks leading to business disruptions and significant costs for system recovery and protection measures[121]. - OPC employs a multi-faceted approach to protect its generation facilities against cyber-attacks, with heightened risks due to the current geopolitical situation[176]. - The use of AI platforms is increasing, but it remains in a developmental phase, exposing OPC to potential cybersecurity risks and operational disruptions[193]. - Compliance with cybersecurity standards is critical, as cyber-attacks could lead to operational delays and increased costs for CPV[241]. Project Development and Execution Risks - The company is working to expand its renewable energy activities in Israel and the United States, potentially incorporating carbon capture technologies[132]. - OPC is pursuing the development and construction of several significant projects concurrently, increasing exposure to development and construction risks[205]. - The construction of the Sorek 2 project faced disruptions due to force majeure notices from contractors and the evacuation of teams, impacting the project's timeline[182]. - Delays in project completion may result in increased costs and forfeiture of collateral or pre-operation investments[252]. - CPV's projects depend on third-party suppliers, and disruptions in supply chains could adversely affect operations and costs[243]. Labor and Human Resource Risks - The company requires qualified personnel to manage operations, and challenges in hiring and retention could adversely affect business performance[113]. - OPC faces challenges in recruiting and retaining skilled employees, which could impact project execution and operational efficiency[187]. Environmental and Compliance Risks - OPC's operations are subject to health and safety risks, including potential civil or criminal procedures due to safety incidents, which may lead to reputational damage[197]. - Legislative changes and stricter environmental standards may increase costs and expose OPC to penalties, sanctions, and remediation expenses[199]. - Environmental regulations may impose significant costs on CPV, requiring investments to comply with stricter standards[245]. - The construction and operation of renewable energy projects face environmental risks, including potential penalties for harming endangered species[251].

Investment and Product Development - The company has invested significant resources in developing products compatible with Microsoft Teams, Zoom, and Cisco Webex, which are critical for maintaining partnerships and market presence[43] - The company is investing in AI and machine learning technologies, including the development of software-based voice productivity solutions under the VoiceAI business line[82] - AudioCodes has expanded its operations to include voice communications solutions for enterprises, contact centers, and service providers, focusing on multiple markets such as VoIP and unified communications[200] - The company has developed a cloud-based service delivery platform, Live Platform, which supports voice connectivity and AI-based communication services, enhancing its offerings across North America, Europe, and Asia Pacific[209] - AudioCodes expanded its portfolio of voice AI services in 2025, introducing Meeting Insights and real-time analytics capabilities, aimed at enhancing service provider offerings and customer experience[212] Geopolitical and Economic Risks - The ongoing geopolitical tensions and military conflicts in Israel have not significantly impacted the company's supply chains or operations to date, although there are risks associated with potential future escalations[37] - Recent military conflicts have led to a review and downgrade of Israel's credit rating by agencies such as Fitch and S&P Global, which could disrupt the business environment and capital raising efforts[39] - The company faces risks from adverse macroeconomic conditions, including inflation and potential recessionary pressures, which could affect its business performance[32] - Political and military conditions in Israel directly affect the company's operations, with recent escalations in conflict since October 2023 impacting business stability[113] - The conflict in Ukraine may result in significant regional instability and adverse effects on global macroeconomic conditions, impacting the company's financial condition[109] Supply Chain and Operational Challenges - There are significant global shortages of critical components necessary for manufacturing, which could hinder the company's ability to meet market demand[35] - Supply chain risks exist due to reliance on a limited number of suppliers for key components, which could disrupt product delivery and increase costs[70][71][72] - The company relies on a small number of sole source suppliers for components, which poses a risk of supply interruptions and potential redesigns of products if alternative sources are not found[73] - The company is heavily reliant on third-party intermediaries for product sales, which limits control over end-user selections and may impact revenue[32] - The company relies on third-party distributors and OEMs for sales, which limits direct access to end-user requirements and may affect product demand[53] Financial Performance and Revenue Risks - The company anticipates fluctuations in quarterly results, which may require revised guidance and could adversely affect share price if expectations are not met[32] - A limited order backlog means that revenue levels are highly dependent on orders received and delivered within the same quarter, which could adversely affect results of operations if expectations are not met[96] - The sales cycles for the company's products typically range from six to twelve months, which complicates revenue predictability and increases costs associated with obtaining orders[76] - Gross margin could be negatively impacted by amortization expenses from acquisitions and increased manufacturing costs, which may adversely affect results of operations[97] - Uncertain economic conditions may lead to reduced consumer spending, adversely impacting sales and potentially increasing credit risk related to customer receivables[98] Compliance and Regulatory Challenges - The company faces risks related to obtaining product certifications from national regulators, which can be time-consuming and may affect market access[80] - The company is subject to various regulations that may increase costs and affect operations, particularly regarding environmentally friendly materials and waste management[137] - Compliance with the General Data Protection Regulation (GDPR) can result in fines of up to EUR 20 million or 4% of total worldwide annual turnover, whichever is higher[144] - The California Consumer Privacy Act (CCPA) requires businesses to provide disclosures regarding personal information collection and to respond to access and deletion requests from California residents[147] - The company may incur significant costs related to compliance with evolving data privacy laws and regulations, which could impact financial performance[149] Competition and Market Dynamics - Intense competition in the industry, including mergers and acquisitions, may hinder the company's ability to maintain profitability[54] - The company competes with major players in various segments, including Oracle, Cisco, and Twilio, across multiple product lines[55][56][57][58][59][60][61][62] - The ongoing shift to IP networks is leading to a decline in demand for media gateway products, adversely affecting revenue from this segment[49] - The transition to cloud-based software poses challenges, as the company primarily generates revenue from on-premises deployments, which may not align with market trends[50] - OEM customers may opt to develop their own solutions or use third-party technologies, potentially reducing demand for the company's products[52] Cybersecurity and Technology Risks - The company is exposed to cybersecurity risks that could damage its brand and result in financial penalties[35] - The company faces significant cybersecurity risks that could adversely affect its operations and financial results, including potential data breaches and legal liabilities[183] - The company is increasingly incorporating open source software into its products, which may introduce vulnerabilities to cyberattacks[185] - The introduction of AI technologies may expose the company to new legal, regulatory, and operational risks, potentially harming financial results[151] - The regulatory landscape for AI in the U.S. is uncertain, with various states enacting their own laws, creating a complex compliance environment[153] Human Resources and Labor Costs - The company has experienced increased wage-related expenses in Israel due to a shortage of skilled R&D employees, impacting recruitment and operational costs[35] - Rising wages and labor-related costs in Israel are expected to impact the company's financial condition and operations due to competition for qualified talent[182] - The company relies heavily on key personnel, including the President and CEO, and any loss of these individuals could materially affect operations[180] Strategic Growth and Future Outlook - The company is committed to expanding its international operations, which presents both growth opportunities and associated risks[35] - The company plans to expand its international operations, which may increase revenues but also exposes it to risks such as contract enforcement difficulties and increased operational costs[178] - The company may pursue acquisitions to expand its business, but such activities could divert resources and disrupt operations, potentially affecting results[191] - The company may require additional financing to support operations and long-term expansion plans, with uncertainty regarding the ability to raise funds on favorable terms[95]